ArticleMacromolecular bioscience2026
Electroconductive Soft Microcarriers for Suspension Culture of Skeletal Muscle Cells.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The advancement of conductive biomaterials is essential for engineering electrically responsive tissues, such as skeletal muscle, cardiac, and neural tissues. Traditional hydrogel-based microcarriers (MCs) lack inherent conductivity, limiting their potential for cell signaling and differentiation. In this study, we present a soft conductive MC system composed of gelatin methacryloyl (GelMA) and poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS), fabricated using microfluidic flow-focusing technology. Material characterization confirms that increasing PEDOT:PSS content significantly improves electrical conductivity and elasticity while maintaining structural integrity. In vitro biocompatibility studies reveal strong C2C12 myoblast attachment and viability, with no significant cytotoxic effects. Furthermore, immunofluorescence and flow cytometry analyses indicate that PEDOT:PSS-containing MCs enhance myogenic early differentiation, as evidenced by increased myosin heavy chain (MyHC) expression, nuclear elongation, and MyHC IF staining. These findings establish GelMA-PEDOT:PSS MCs as a promising bioelectronic platform for tissue engineering applications, with potential implications for skeletal muscle regeneration. Future studies should explore dynamic electrical stimulation strategies to further optimize bio-functionality and cell-specific responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.